Arcutis Biotherapeutics (NASDAQ:ARQT) CFO Latha Vairavan Sells 1,341 Shares

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) CFO Latha Vairavan sold 1,341 shares of the stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $31,661.01. Following the completion of the transaction, the chief financial officer directly owned 86,413 shares in the company, valued at $2,040,210.93. The trade was a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Latha Vairavan also recently made the following trade(s):

• On Monday, March 2nd, Latha Vairavan sold 2,853 shares of Arcutis Biotherapeutics stock. The shares were sold at an average price of $25.18, for a total value of $71,838.54.

Arcutis Biotherapeutics Trading Up 3.2%

NASDAQ:ARQT opened at $24.17 on Thursday. Arcutis Biotherapeutics, Inc. has a 1-year low of $12.42 and a 1-year high of $31.77. The business’s 50-day moving average price is $23.78 and its two-hundred day moving average price is $25.78. The company has a current ratio of 3.17, a quick ratio of 2.99 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of -172.63 and a beta of 1.58.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its earnings results on Wednesday, May 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative net margin of 4.29% and a negative return on equity of 10.26%. The company had revenue of $105.40 million during the quarter, compared to analyst estimates of $103.68 million. On average, equities analysts expect that Arcutis Biotherapeutics, Inc. will post 0.18 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ARQT shares. Mizuho reduced their price target on shares of Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating on the stock in a research report on Monday, March 2nd. Needham & Company LLC reissued a “buy” rating and set a $36.00 price target on shares of Arcutis Biotherapeutics in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Friday, March 27th. HC Wainwright lifted their price target on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Wall Street Zen cut shares of Arcutis Biotherapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.00.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong commercial performance and clinical progress: Q1 net product revenue for ZORYVE was $105.4M (up 65% YoY), the company reported positive operating cash flow, submitted an sNDA to expand ZORYVE to infants 3–24 months, completed enrollment in a pediatric MUSE trial, initiated Phase 1a/1b for ARQ‑234, and expanded the salesforce and primary care/pediatrics buildout. These developments support continued top-line growth and pipeline optionality. Read More.
• Positive Sentiment: Analyst stance remains constructive: Brokerages maintain a consensus “Moderate Buy” and a mid‑$30s consensus target, which can buoy investor sentiment as commercial momentum continues. Read More.
• Neutral Sentiment: Mixed Q1 financials: Revenue beat estimates ($105.4M vs. ~$103.7M) but GAAP EPS missed materially (loss of $0.09 vs. expected loss of $0.02). The top-line strength supports commercialization, but the EPS miss highlights continued margin/expense pressure as the company invests in growth. Read More.
• Negative Sentiment: Insider selling: Multiple insiders (including director and executives) sold shares in early May under pre‑arranged Rule 10b5‑1 plans to cover tax withholding on vested awards. While filings state routine/tax reasons, clustered sales can raise short‑term concerns about insider exposure and add selling pressure. Read More.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of ARQT. Suvretta Capital Management LLC grew its position in shares of Arcutis Biotherapeutics by 14.2% in the 4th quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company’s stock valued at $347,435,000 after purchasing an additional 1,486,000 shares during the period. Jennison Associates LLC grew its position in shares of Arcutis Biotherapeutics by 10.3% in the 3rd quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock valued at $230,990,000 after purchasing an additional 1,144,714 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Arcutis Biotherapeutics by 1,228.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,166,348 shares of the company’s stock valued at $33,872,000 after purchasing an additional 1,078,546 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Arcutis Biotherapeutics during the 4th quarter worth about $26,136,000. Finally, State Street Corp increased its holdings in Arcutis Biotherapeutics by 18.2% during the 4th quarter. State Street Corp now owns 5,488,301 shares of the company’s stock worth $159,380,000 after purchasing an additional 846,986 shares in the last quarter.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.